Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2020

August 2020 | 1084 pages | ID: HC68A7CA6E4EN
Global Markets Direct

Abstracts

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Pipeline Review, H2 2020, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 44, 40, 1, 14, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 3, 2, 2 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2020
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Affimed GmbH
Alfasigma SpA
Alissa Pharma
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
Apollomics Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avipep Pty Ltd
Bayer AG
Biohaven Pharmaceutical Holding Company Ltd
Bristol-Myers Squibb Co
Carrick Therapeutics Ltd
Catalent Inc
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celularity Inc
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Children's National Research Institute
Chipscreen Biosciences Ltd
Constellation Pharmaceuticals Inc
CSL Ltd
CStone Pharmaceuticals Co Ltd
Curis Inc
Dragonfly Therapeutics Inc
Eutilex Co Ltd
Faron Pharmaceuticals Oy
Gibson Oncology LLC
Gilead Sciences Inc
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
Helocyte Biosciences Inc
HRAIN Biotechnology Co Ltd
Immune Cell Inc
Immunomedics Inc
Incuron LLC
Incyte Corp
Inhibrx Inc
Innovent Biologics Inc
Kuur Therapeutics Ltd
Magenta Therapeutics Inc
Marker Therapeutics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec BV & Co KG
NantKwest Inc
NewBio Therapeutics Inc
Northlake International LLC
OncoTartis Inc
Ono Pharmaceutical Co Ltd
Protheragen Inc
Rafael Pharmaceuticals Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rich Pharmaceuticals Inc
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
Seattle Genetics Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shattuck Labs Inc
Sichuan Kelun Pharmaceutical Co Ltd
SpecificiT Pharma Inc
Tacitus Therapeutics Inc
TaiGen Biotechnology Co Ltd
Taiwan Liposome Co Ltd
Tessa Therapeutics Ltd
Tevogen Bio Inc
Trillium Therapeutics Inc
Tyme Technologies Inc
Viracta Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd